|
|
|
|
|
|
|
|
|
|
Analyst Blog
....We note that Amgen stumbled with its oncology pipeline earlier this month as well when its experimental ovarian cancer treatment, trebananib, failed to meet the secondary endpoint of overall survival in a late-stage study. Although trebananib had achieved the primary endpoint of the study, overall survival is an important criterion for gaining FDA approval. Moreover, the rate of discontinuation due to adverse events was much higher in the trebananib arm compared to the control arm (20% versus 7%).....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.